Statins for primary prevention: Strategic options to save lives and money

Journal of the Royal Society of Medicine

Volumn 97, Issue 2, 2004, Pages 66-71

  Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY RISK; DOSE RESPONSE; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LOW DRUG DOSE; PRESCRIPTION; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE;

EID: 1242338065     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.97.2.66     Document Type: Review

References (23)

1. Gaw A, Packard CJ. At what level of coronary heart disease risk should a statin be prescribed? Curr Opin Lipidol 2000;11:363-7
2. Jackson PR, Ramsay LE. Debate: at what level of coronary heart disease risk should a statin be prescribed? Clin Opin Lipidol 2000;11:357-61
3. Rose G. Environmental health: problems and prospects. J R Coll Physicians Lond 1991;25:48-52
4. Pyorala K, DeBacker G, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994;110:121-61
5. Wood D, de Backer G, Faergeman O, Graham I, Manda G, Pyorala K, together with members of the Task Force. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 1998;140:199-270
6. de Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Europ J Cardiovasc Prev Rehab. 2003;10:S1-S10
7. Executive summary of the third report of the NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
8. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 1986;256:2823-8
9. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on coronary events in the West of Scotland Coronary Prevention Study. Circulation 1998;97:1440-5
10. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT. Relationship between plasma LDL cholesterol concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial (CARE). Circulation 1998; 97:1446-52
11. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7
12. National Service Framework for Coronary Heart Disease [www.doh.gov.uk/nsf/coronary.htm] accessed 12 December 2003
13. Scottish Intercollegiate Guidelines Network. Lipids and the Primary Prevention of Coronary Heart Disease:SIGN, Publication No. 40. Edinburgh: Royal College of Physicians of Edinburgh, 1999
14. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7
15. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
18. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
19. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
22. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
23. The PPP Project Investigators. Design, rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project: a combined analysis of three large-scale randomized trials: Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76: 899-905